Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. - Park JW; Curtis JR; Choi SR; Kim MJ; Ha YJ; Kang EH; Lee YJ; Lee EB (Arthritis & rheumatology (Hoboken, N.J.), 2023)